MX363010B - Tratamiento de la atrofia de piel con una combinacion de acido triyodotiroacetico (triac) y dehidroepiandrosterona (dhea). - Google Patents
Tratamiento de la atrofia de piel con una combinacion de acido triyodotiroacetico (triac) y dehidroepiandrosterona (dhea).Info
- Publication number
- MX363010B MX363010B MX2017006516A MX2017006516A MX363010B MX 363010 B MX363010 B MX 363010B MX 2017006516 A MX2017006516 A MX 2017006516A MX 2017006516 A MX2017006516 A MX 2017006516A MX 363010 B MX363010 B MX 363010B
- Authority
- MX
- Mexico
- Prior art keywords
- triac
- dhea
- combination
- skin atrophy
- skin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
El objetivo del presente estudio es investigar el efecto de una combinación del ácido triyodotiroacético (TRIAC) y dehidroepiandrosterona (DHEA) en comparación con el TRIAC, DHEA o un placebo solo sobre el efecto inducido por corticosteroides en la síntesis de colágeno en humanos. Participaron seis voluntarios varones humanos sanos con edades de 40-65 años. Cuatro zonas de la piel abdominal se pre-trataron durante 3 semanas con crema de valerato de betametasona. Las mismas áreas después se trataron con una de las siguientes alternativas en el mismo vehículo de crema: TRIAC, DHEA, TRIAC+DHEA y placebo durante 2 semanas. Después se suscitaron ampollas de succión en cada una de estas áreas con una bomba de vacío. El fluido de ampolla de cada área se recolectó y se congeló hasta su análisis. El análisis del propéptido amino terminal del procolágeno tipo I humano (PINP) en el fluido de ampolla de succión se realizó con el uso de un kit de inmunoensayo disponible comercialmente (Orion Diagnostics). Este estudio por primera vez ha mostrado que una combinación de TRIAC y DHEA podría estimular eficazmente la síntesis de colágeno en la piel pretratada con valerato de betametasona, mostrado por un incremento en PINP, y que la combinación fue más eficaz que el TRIAC o la DHEA solos. Esta combinación podría ser utilizada para tratar con eficacia la atrofia de piel inducida por corticosteroides en atrofia de piel. También se podría utilizar para tratar la atrofia de piel debida a otras circunstancias, tales como la piel dañada por ejemplo por el sol y atrofiaa de piel debida a una alta edad. Otra aplicación interesante sería combinar el TRIAC y DHEA con un potente corticosteroide con el fin de evitar la atrofia de piel inducida por corticosteroides. Si esta combinación todavía es eficaz en el tratamiento de eczema y psoriasis y sin el riesgo de atrofia de piel, esta combinación será un gran avance para el uso de corticosteroides tópicos potentes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201470737 | 2014-11-25 | ||
PCT/EP2015/077401 WO2016083325A1 (en) | 2014-11-25 | 2015-11-24 | Treatment of skin atrophy with a combination of triiodothyroacetic acid (triac) and dehydroepiandrosterone (dhea) |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2017006516A MX2017006516A (es) | 2018-01-25 |
MX363010B true MX363010B (es) | 2019-03-04 |
Family
ID=52133757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017006516A MX363010B (es) | 2014-11-25 | 2015-11-24 | Tratamiento de la atrofia de piel con una combinacion de acido triyodotiroacetico (triac) y dehidroepiandrosterona (dhea). |
Country Status (18)
Country | Link |
---|---|
US (2) | US10413555B2 (es) |
EP (1) | EP3223808B1 (es) |
JP (1) | JP6666911B2 (es) |
KR (1) | KR20170086597A (es) |
CN (1) | CN106999457B (es) |
AU (1) | AU2015352677B2 (es) |
BR (1) | BR112017010778A2 (es) |
CA (1) | CA2968611A1 (es) |
DK (1) | DK3223808T3 (es) |
ES (1) | ES2714078T3 (es) |
HU (1) | HUE042970T2 (es) |
IL (1) | IL252203A0 (es) |
MX (1) | MX363010B (es) |
PL (1) | PL3223808T3 (es) |
PT (1) | PT3223808T (es) |
RU (1) | RU2017121884A (es) |
WO (1) | WO2016083325A1 (es) |
ZA (1) | ZA201702989B (es) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH642851A5 (en) | 1980-02-13 | 1984-05-15 | Berema Sa | Medicinal compositions for the treatment of cellulite |
GB9214202D0 (en) | 1992-07-03 | 1992-08-12 | Leo Pharm Prod Ltd | Chemical compounds |
AU6476996A (en) | 1995-06-07 | 1996-12-30 | Karo Bio Ab | Novel uses for thyroid hormones or thyroid hormone-like comp ounds |
EP1021204B1 (en) | 1997-09-26 | 2005-12-28 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
FR2808683B1 (fr) | 2000-05-15 | 2003-05-23 | Oreal | Utilisation de la dhea et/ou ses precurseurs et derives chimiques et/ou biologiques, dans une composition notamment cosmetique, pour prevenir ou traiter l'atrophie de l'epiderme |
US20050271739A1 (en) * | 2004-06-08 | 2005-12-08 | Wang Xiang H | Methods and compositions for accelerating alcohol metabolism |
US20080305096A1 (en) * | 2007-06-07 | 2008-12-11 | Unicity International, Inc. | Method and composition for providing controlled delivery of biologically active substances |
US20100009970A1 (en) * | 2008-03-19 | 2010-01-14 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
-
2015
- 2015-11-24 ES ES15798133T patent/ES2714078T3/es active Active
- 2015-11-24 RU RU2017121884A patent/RU2017121884A/ru not_active Application Discontinuation
- 2015-11-24 US US15/528,882 patent/US10413555B2/en not_active Expired - Fee Related
- 2015-11-24 WO PCT/EP2015/077401 patent/WO2016083325A1/en active Application Filing
- 2015-11-24 DK DK15798133.3T patent/DK3223808T3/en active
- 2015-11-24 CN CN201580063734.7A patent/CN106999457B/zh not_active Expired - Fee Related
- 2015-11-24 BR BR112017010778A patent/BR112017010778A2/pt not_active Application Discontinuation
- 2015-11-24 AU AU2015352677A patent/AU2015352677B2/en not_active Ceased
- 2015-11-24 EP EP15798133.3A patent/EP3223808B1/en not_active Not-in-force
- 2015-11-24 HU HUE15798133A patent/HUE042970T2/hu unknown
- 2015-11-24 JP JP2017528849A patent/JP6666911B2/ja not_active Expired - Fee Related
- 2015-11-24 KR KR1020177016732A patent/KR20170086597A/ko not_active Application Discontinuation
- 2015-11-24 MX MX2017006516A patent/MX363010B/es unknown
- 2015-11-24 PL PL15798133T patent/PL3223808T3/pl unknown
- 2015-11-24 CA CA2968611A patent/CA2968611A1/en not_active Abandoned
- 2015-11-24 PT PT15798133T patent/PT3223808T/pt unknown
-
2017
- 2017-04-28 ZA ZA201702989A patent/ZA201702989B/en unknown
- 2017-05-10 IL IL252203A patent/IL252203A0/en unknown
-
2019
- 2019-03-22 US US16/362,576 patent/US20190216822A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20190216822A1 (en) | 2019-07-18 |
PT3223808T (pt) | 2019-02-04 |
JP6666911B2 (ja) | 2020-03-18 |
EP3223808B1 (en) | 2019-01-09 |
CN106999457B (zh) | 2020-02-11 |
AU2015352677B2 (en) | 2019-10-24 |
ES2714078T3 (es) | 2019-05-27 |
IL252203A0 (en) | 2017-07-31 |
RU2017121884A3 (es) | 2019-04-05 |
JP2017535590A (ja) | 2017-11-30 |
US20170319598A1 (en) | 2017-11-09 |
CN106999457A (zh) | 2017-08-01 |
AU2015352677A1 (en) | 2017-05-11 |
BR112017010778A2 (pt) | 2018-01-09 |
US10413555B2 (en) | 2019-09-17 |
WO2016083325A1 (en) | 2016-06-02 |
RU2017121884A (ru) | 2018-12-26 |
ZA201702989B (en) | 2019-10-30 |
CA2968611A1 (en) | 2016-06-02 |
EP3223808A1 (en) | 2017-10-04 |
DK3223808T3 (en) | 2019-03-25 |
KR20170086597A (ko) | 2017-07-26 |
MX2017006516A (es) | 2018-01-25 |
HUE042970T2 (hu) | 2019-07-29 |
PL3223808T3 (pl) | 2019-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY199033A (en) | Keratin treatment formulations and methods | |
MX2017013983A (es) | Uso de agentes activos durante tratamientos quimicos. | |
MX2019013657A (es) | Metodo cosmetico para reducir las señales dermatologicas de envejecimiento. | |
PH12018502634A1 (en) | Topical compositions of apremilast | |
EA201590709A1 (ru) | Комбинированная терапия и ее применение для лечения димиелинизирующих расстройств | |
WO2014176128A3 (en) | Compositions and methods for the therapy and diagnosis of influenza | |
MX363182B (es) | Composiciones que comprenden mezclas de alcanos semifluorados. | |
SG10201808104RA (en) | Cenicriviroc for the treatment of fibrosis | |
BR112015001847A8 (pt) | Composições e tratamento para doenças e distúrbios nos olhos | |
EA201692334A1 (ru) | Кортикостероидные композиции для местного применения | |
MX2018000421A (es) | Composiciones de retinoides topicos. | |
WO2015198150A3 (en) | Methods and compositions of bile acids and salts for reduction of fat | |
MX2021010989A (es) | Formulacion que incluye una combinacion de la hormona beta-endorfina y adrenocorticotropica. | |
BR112018012022A2 (pt) | ?composição, e, método para tratamento ou redução do risco de colestase intra-hepática? | |
RU2017134440A (ru) | Композиции для местного применения, содержащие кортикостероид | |
WO2013152193A3 (en) | Methods of treating proliferative disorders with malate or derivatives thereof | |
MX337195B (es) | Composiciones y metodos para tratar condiciones dermatologicas. | |
BR112019017393A2 (pt) | formulações de evolocumab de baixa viscosidade, alta concentração e métodos para produzir as mesmas | |
IN2014DE01913A (es) | ||
BR112019006880A2 (pt) | compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos | |
WO2014190179A3 (en) | Urea silicon gel for scars and hydration treatment and method of using same | |
MX2017006516A (es) | Tratamiento de la atrofia de piel con una combinacion de acido triyodotiroacetico (triac) y dehidroepiandrosterona (dhea). | |
WO2015063613A3 (en) | Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents | |
BR112018013558A2 (pt) | método de tratamento de uma doença hepática em um indivíduo, método de uso de um inibidor de caspase, método para diminuir ou sustentar uma classificação meld ou seus componentes, método para tratar, diminuir ou sustentar uma classificação meld ou seus componentes, método para tratar, diminuir ou sustentar uma classificação de child-pugh ou seus componentes, composição farmacêutica que compreende um inibidor de caspase, kit, método de tratamento, método de tratamento de cirrose hepática e prevenção de uma classificação meld elevada, método de tratamento de cirrose hepática e prevenção de uma classificação de child-pugh elevada | |
WO2016145362A3 (en) | Inhibitors of dek protein and related methods |